AU3966395A - Microbial synthesis of hiv protease inhibitors - Google Patents
Microbial synthesis of hiv protease inhibitorsInfo
- Publication number
- AU3966395A AU3966395A AU39663/95A AU3966395A AU3966395A AU 3966395 A AU3966395 A AU 3966395A AU 39663/95 A AU39663/95 A AU 39663/95A AU 3966395 A AU3966395 A AU 3966395A AU 3966395 A AU3966395 A AU 3966395A
- Authority
- AU
- Australia
- Prior art keywords
- hiv
- compound
- aids
- treatment
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000813 microbial effect Effects 0.000 title description 7
- 230000015572 biosynthetic process Effects 0.000 title description 6
- 239000004030 hiv protease inhibitor Substances 0.000 title description 4
- 238000003786 synthesis reaction Methods 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 69
- 208000030507 AIDS Diseases 0.000 claims description 54
- 238000011282 treatment Methods 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 26
- 208000015181 infectious disease Diseases 0.000 claims description 18
- 108010010369 HIV Protease Proteins 0.000 claims description 16
- 230000036983 biotransformation Effects 0.000 claims description 15
- 230000005764 inhibitory process Effects 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000002194 synthesizing effect Effects 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 67
- 241000725303 Human immunodeficiency virus Species 0.000 description 36
- 239000000047 product Substances 0.000 description 33
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 33
- 239000000203 mixture Substances 0.000 description 31
- 206010001513 AIDS related complex Diseases 0.000 description 30
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 29
- 235000019439 ethyl acetate Nutrition 0.000 description 29
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 26
- 238000004128 high performance liquid chromatography Methods 0.000 description 19
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 239000003112 inhibitor Substances 0.000 description 18
- 239000002904 solvent Substances 0.000 description 18
- 239000002609 medium Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 16
- 229960002555 zidovudine Drugs 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 14
- -1 oatmeal Substances 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 230000014759 maintenance of location Effects 0.000 description 13
- 229920001817 Agar Polymers 0.000 description 12
- 239000008272 agar Substances 0.000 description 12
- 229940044613 1-propanol Drugs 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 11
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 238000005481 NMR spectroscopy Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 8
- 150000002924 oxiranes Chemical class 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 7
- 208000031886 HIV Infections Diseases 0.000 description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 229940041514 candida albicans extract Drugs 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 238000000855 fermentation Methods 0.000 description 7
- 230000004151 fermentation Effects 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000002002 slurry Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000012138 yeast extract Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 208000037357 HIV infectious disease Diseases 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- 239000004365 Protease Substances 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 239000003443 antiviral agent Substances 0.000 description 6
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 6
- 239000002955 immunomodulating agent Substances 0.000 description 6
- 229940121354 immunomodulator Drugs 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 229940126062 Compound A Drugs 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 208000007766 Kaposi sarcoma Diseases 0.000 description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000002024 ethyl acetate extract Substances 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 239000012065 filter cake Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 235000011007 phosphoric acid Nutrition 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- 241000187747 Streptomyces Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 229940121357 antivirals Drugs 0.000 description 4
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 4
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 4
- 235000019797 dipotassium phosphate Nutrition 0.000 description 4
- 210000003714 granulocyte Anatomy 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 229960000689 nevirapine Drugs 0.000 description 4
- 239000002777 nucleoside Substances 0.000 description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 3
- 101150041968 CDC13 gene Proteins 0.000 description 3
- 101710205625 Capsid protein p24 Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010027044 HIV Core Protein p24 Proteins 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 239000007836 KH2PO4 Substances 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 101710177166 Phosphoprotein Proteins 0.000 description 3
- 108010009736 Protein Hydrolysates Proteins 0.000 description 3
- 101710149279 Small delta antigen Proteins 0.000 description 3
- 235000019764 Soybean Meal Nutrition 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 230000002924 anti-infective effect Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 229960005475 antiinfective agent Drugs 0.000 description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 229940045184 malt extract Drugs 0.000 description 3
- 229960002160 maltose Drugs 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 3
- 235000019796 monopotassium phosphate Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- NIPZZXUFJPQHNH-UHFFFAOYSA-N pyrazine-2-carboxylic acid Chemical compound OC(=O)C1=CN=CC=N1 NIPZZXUFJPQHNH-UHFFFAOYSA-N 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000004455 soybean meal Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000008399 tap water Substances 0.000 description 3
- 235000020679 tap water Nutrition 0.000 description 3
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 241001446247 uncultured actinomycete Species 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- LOPKSXMQWBYUOI-DTWKUNHWSA-N (1r,2s)-1-amino-2,3-dihydro-1h-inden-2-ol Chemical compound C1=CC=C2[C@@H](N)[C@@H](O)CC2=C1 LOPKSXMQWBYUOI-DTWKUNHWSA-N 0.000 description 2
- XKLJLHAPJBUBNL-UHFFFAOYSA-N 12-methyltetradecanoic acid Chemical compound CCC(C)CCCCCCCCCCC(O)=O XKLJLHAPJBUBNL-UHFFFAOYSA-N 0.000 description 2
- CNQCWYFDIQSALX-UHFFFAOYSA-N 3-(chloromethyl)pyridine Chemical compound ClCC1=CC=CN=C1 CNQCWYFDIQSALX-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 2
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102100031939 Erythropoietin Human genes 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-OWMBCFKOSA-N L-ribopyranose Chemical compound O[C@H]1COC(O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-OWMBCFKOSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- DKXNBNKWCZZMJT-UHFFFAOYSA-N O4-alpha-D-Mannopyranosyl-D-mannose Natural products O=CC(O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O DKXNBNKWCZZMJT-UHFFFAOYSA-N 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- VSQUZVLNMULDCY-UHFFFAOYSA-N [O].C1=CC=NC=C1 Chemical compound [O].C1=CC=NC=C1 VSQUZVLNMULDCY-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- PNNNRSAQSRJVSB-BXKVDMCESA-N aldehydo-L-rhamnose Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 description 2
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004581 coalescence Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 208000001763 cytomegalovirus retinitis Diseases 0.000 description 2
- 239000012225 czapek media Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 229940044627 gamma-interferon Drugs 0.000 description 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- ZOCYQVNGROEVLU-UHFFFAOYSA-N isopentadecanoic acid Chemical compound CC(C)CCCCCCCCCCCC(O)=O ZOCYQVNGROEVLU-UHFFFAOYSA-N 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229940042443 other antivirals in atc Drugs 0.000 description 2
- 235000010603 pastilles Nutrition 0.000 description 2
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 2
- 229960004448 pentamidine Drugs 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 201000003450 persistent generalized lymphadenopathy Diseases 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229960005335 propanol Drugs 0.000 description 2
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- ATEBXHFBFRCZMA-VXTBVIBXSA-N rifabutin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC(=C2N3)C(=O)C=4C(O)=C5C)C)OC)C5=C1C=4C2=NC13CCN(CC(C)C)CC1 ATEBXHFBFRCZMA-VXTBVIBXSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Inorganic materials [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 2
- 229960001082 trimethoprim Drugs 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 229930195724 β-lactose Natural products 0.000 description 2
- UQZSVIGPZAULMV-DKWTVANSSA-N (2s)-2,4-diamino-4-oxobutanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.OC(=O)[C@@H](N)CC(N)=O UQZSVIGPZAULMV-DKWTVANSSA-N 0.000 description 1
- XOYXESIZZFUVRD-UVSAJTFZSA-N (2s,3s,4r,5s,6s)-6-[(2r,3r,4r,5s,6r)-6-[(2r,3s,4r,5s,6r)-5-acetamido-6-[(2r,3r,4r,5s,6r)-4-acetyloxy-6-[(2r,3r,4r,5s,6r)-4-acetyloxy-6-[(2r,3r,4r,5s,6s)-4-acetyloxy-5-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-3-yl]oxy-5-hydroxy-2-(hydroxymethyl)oxan-3-yl]ox Chemical compound CC(=O)O[C@@H]1[C@H](O)[C@@H](OC)O[C@H](CO)[C@H]1O[C@@H]1[C@@H](O)[C@@H](OC(C)=O)[C@H](O[C@@H]2[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O[C@@H]4[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]5[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]6[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]7[C@H]([C@@H](OC(C)=O)[C@H](OC)[C@@H](CO)O7)O)[C@@H](CO)O6)O)[C@H](O5)C(O)=O)O)[C@@H](CO)O4)O)[C@@H](CO)O3)NC(C)=O)[C@@H](CO)O2)O)[C@@H](CO)O1 XOYXESIZZFUVRD-UVSAJTFZSA-N 0.000 description 1
- VQWNFBGVGJSEIS-GOSISDBHSA-N (4s)-6-chloro-4-cyclopropyl-4-(2-pyridin-2-ylethynyl)-1,3-dihydroquinazolin-2-one Chemical group C([C@]1(C2CC2)NC(=O)NC2=CC=C(C=C21)Cl)#CC1=CC=CC=N1 VQWNFBGVGJSEIS-GOSISDBHSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-XVKPBYJWSA-N (R)-camphorsulfonic acid Chemical class C1C[C@]2(CS(O)(=O)=O)C(=O)C[C@H]1C2(C)C MIOPJNTWMNEORI-XVKPBYJWSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- LJXGLQWLORNQQY-UHFFFAOYSA-N 2-(4-chloro-2-methylphenoxy)propanoic acid;3,6-dichloro-2-methoxybenzoic acid;n-methylmethanamine Chemical compound CNC.CNC.COC1=C(Cl)C=CC(Cl)=C1C(O)=O.OC(=O)C(C)OC1=CC=C(Cl)C=C1C LJXGLQWLORNQQY-UHFFFAOYSA-N 0.000 description 1
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 description 1
- YOWQWFMSQCOSBA-UHFFFAOYSA-N 2-methoxypropene Chemical compound COC(C)=C YOWQWFMSQCOSBA-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- MFEILWXBDBCWKF-UHFFFAOYSA-N 3-phenylpropanoyl chloride Chemical compound ClC(=O)CCC1=CC=CC=C1 MFEILWXBDBCWKF-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- GJOHLWZHWQUKAU-UHFFFAOYSA-N 5-azaniumylpentan-2-yl-(6-methoxyquinolin-8-yl)azanium;dihydrogen phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 GJOHLWZHWQUKAU-UHFFFAOYSA-N 0.000 description 1
- VJXSSYDSOJBUAV-UHFFFAOYSA-N 6-(2,5-dimethoxy-benzyl)-5-methyl-pyrido[2,3-d]pyrimidine-2,4-diamine Chemical compound COC1=CC=C(OC)C(CC=2C(=C3C(N)=NC(N)=NC3=NC=2)C)=C1 VJXSSYDSOJBUAV-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000032484 Accidental exposure to product Diseases 0.000 description 1
- 241000427202 Adria Species 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010003581 Asymptomatic HIV infection Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- CIUUIPMOFZIWIZ-UHFFFAOYSA-N Bropirimine Chemical compound NC1=NC(O)=C(Br)C(C=2C=CC=CC=2)=N1 CIUUIPMOFZIWIZ-UHFFFAOYSA-N 0.000 description 1
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 208000006081 Cryptococcal meningitis Diseases 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241000533845 Enterolobium cyclocarpum Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229940122440 HIV protease inhibitor Drugs 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108010054710 IMREG-1 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010069803 Injury associated with device Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000544912 Melanoides Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027209 Meningitis cryptococcal Diseases 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- NSGDYZCDUPSTQT-UHFFFAOYSA-N N-[5-bromo-1-[(4-fluorophenyl)methyl]-4-methyl-2-oxopyridin-3-yl]cycloheptanecarboxamide Chemical compound Cc1c(Br)cn(Cc2ccc(F)cc2)c(=O)c1NC(=O)C1CCCCCC1 NSGDYZCDUPSTQT-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010071384 Peptide T Proteins 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 239000004187 Spiramycin Substances 0.000 description 1
- 241000187180 Streptomyces sp. Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 101800001703 Thymopentin Proteins 0.000 description 1
- 102400000160 Thymopentin Human genes 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- HIINQLBHPIQYHN-JTQLQIEISA-N Tyr-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 HIINQLBHPIQYHN-JTQLQIEISA-N 0.000 description 1
- MUCRYNWJQNHDJH-OADIDDRXSA-N Ursonic acid Chemical compound C1CC(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C MUCRYNWJQNHDJH-OADIDDRXSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- NOQXXYIGRPAZJC-VIFPVBQESA-N [(2s)-oxiran-2-yl]methyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC[C@H]1OC1 NOQXXYIGRPAZJC-VIFPVBQESA-N 0.000 description 1
- MIOPJNTWMNEORI-OMNKOJBGSA-N [(4s)-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl]methanesulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-OMNKOJBGSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960005327 acemannan Drugs 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000010936 aqueous wash Methods 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229950009494 bropirimine Drugs 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- DKVNPHBNOWQYFE-UHFFFAOYSA-N carbamodithioic acid Chemical compound NC(S)=S DKVNPHBNOWQYFE-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- 238000007621 cluster analysis Methods 0.000 description 1
- 150000001868 cobalt Chemical class 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000002281 colonystimulating effect Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 239000007771 core particle Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940087451 cytovene Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- CVLAEJNQNKXNNN-UHFFFAOYSA-N diazepin-4-one Chemical compound O=C1C=CC=NN=C1 CVLAEJNQNKXNNN-UHFFFAOYSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012990 dithiocarbamate Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- DLDIDQIZPBIVNQ-UHFFFAOYSA-N hydron;2-methylpropan-2-amine;chloride Chemical compound Cl.CC(C)(C)N DLDIDQIZPBIVNQ-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- YIAPLDFPUUJILH-UHFFFAOYSA-N indan-1-ol Chemical compound C1=CC=C2C(O)CCC2=C1 YIAPLDFPUUJILH-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 1
- 229960005225 mifamurtide Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- DEMUAWGOQNIABC-UHFFFAOYSA-N n',n'-ditert-butyloxamide Chemical compound CC(C)(C)N(C(C)(C)C)C(=O)C(N)=O DEMUAWGOQNIABC-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000006877 oatmeal agar Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002897 organic nitrogen compounds Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- NOQXXYIGRPAZJC-UHFFFAOYSA-N oxiran-2-ylmethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCC1OC1 NOQXXYIGRPAZJC-UHFFFAOYSA-N 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- ZAEQTGTVGUJEFV-UHFFFAOYSA-N phenylmethanesulfonate;pyridin-1-ium Chemical compound C1=CC=[NH+]C=C1.[O-]S(=O)(=O)CC1=CC=CC=C1 ZAEQTGTVGUJEFV-UHFFFAOYSA-N 0.000 description 1
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 1
- 229950001030 piritrexim Drugs 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960005179 primaquine Drugs 0.000 description 1
- 239000013587 production medium Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 108700018720 recombinant interferon alpha 2b-like Proteins 0.000 description 1
- 108010043277 recombinant soluble CD4 Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229960000885 rifabutin Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Substances [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 235000019372 spiramycin Nutrition 0.000 description 1
- 229960001294 spiramycin Drugs 0.000 description 1
- 229930191512 spiramycin Natural products 0.000 description 1
- 230000028070 sporulation Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Natural products CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- NASIOHFAYPRIAC-JTQLQIEISA-N tert-butyl (3s)-3-(tert-butylcarbamoyl)piperazine-1-carboxylate Chemical compound CC(C)(C)NC(=O)[C@@H]1CN(C(=O)OC(C)(C)C)CCN1 NASIOHFAYPRIAC-JTQLQIEISA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- PSWFFKRAVBDQEG-YGQNSOCVSA-N thymopentin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PSWFFKRAVBDQEG-YGQNSOCVSA-N 0.000 description 1
- 229960004517 thymopentin Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229960001099 trimetrexate Drugs 0.000 description 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000007106 trypticase soy broth agar Substances 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229940100050 virazole Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
TITLE OF THE INVENTION
MICROBIAL SYNTHESIS OF HIV PROTEASE INHIBITORS
BACKGROUND OF THE INVENTION The present application is related to Merck 19276, 18996 and 18996IA.
The present invention is concerned with a novel process for synthesizing compounds that inhibit the protease encoded by human immunodeficiency virus (HIV), and in particular certain oligopeptide analogs, such as derivatives of Compound J in the Examples below. These compounds are of value in the prevention of infection by HIV, the treatment of infection by HIV and the treatment of the resulting acquired immune deficiency syndrome (AIDS). These compounds are also useful for inhibiting renin and other proteases. A retrovirus designated human immunodeficiency virus
(HIV) is the etiological agent of the complex disease that includes progressive destruction of the immune system (acquired immune deficiency syndrome; AIDS) and degeneration of the central and peripheral nervous system. This virus was previously known as LAV, HTLV-III, or ARV. A common feature of retrovirus replication is the extensive post-translational processing of precursor polyproteins by a viral ly encoded protease to generate mature viral proteins required for virus assembly and function. Inhibition of this processing prevents the production of normally infectious virus. For example, Kohl, N. E. ct ai, Proc. Nat'l Acacl. Sci., H5, 4686 (1988) demonstrated that genetic inactivation of the HIV encoded protease resulted in the production of immature, non-infectious virus particles. These results indicate that inhibition of the HIV protease represents a viable method for the treatment of AIDS and the prevention or treatment of infection by HIV. The nucleotide sequence of HIV shows the presence of a roj gene in one open reading frame [Ratner, L. ct ai. Nature. 313, 277 ( 1985) . Amino acid sequence homology provides evidence that the go! sequence encodes reverse transcriptase, an endonuclease and an HIV protease [Toh, H. et ai, EMBO J., 4, 1267 ( 1985); Power, M. D. ct ai.
/12492 PC17US95/13628
- 2
Science, 231 , 1567 ( 1986); Pearl, L. H. et ai, Nature, 329, 351 ( 1987)]. Compounds, including certain oligopeptide analogs that can be made from the novel processes of this invention are inhibitors of HIV protease. See EPO 541 , 168, which published on May 12, 1993. See also, for example, Compound J therein.
Previously, the synthesis of Compound J and related compounds was accomplished via a 12-step procedure. This procedure is described in EPO 541 , 168. The extreme length of this route (12 steps), renders this process time consuming and labor intensive, and it requires the use of many presently expensive reagents and a presently expensive starting material. A route requiring fewer reaction steps and reagents would provide desirable economical and time-saving benefits.
Applicants have identified and synthesized a variety of derivatives of Compound J, by incubating Compound J with a selected microbial system, MA7065. The new compounds are active and potent inhibitors of HIV protease.
SUMMARY OF THE INVENTION
Biotransformation products of a fermentation with culture MA7065 are potent HIV protease inhibitors. These products are useful in the prevention or treatment of infection by HIV and in the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
DETAILED DESCRIPTION OF THE INVENTION
A method is disclosed for synthesizing biotransformation products of the Compound J, having the structure:
or salt or hydrate thereof, comprising the steps of
(a) providing a culture of MA7065;
(b) incubating said culture with Compound J;
(c) isolating biotransformation products comprising:
Compound A
Compound C1
Compound C2
Compound D
Compound E
or salt or hydrate thereof. A preferred compound is compound A. Also covered are the purified biotransformation products of this method, as well as the corresponding chemical compounds.
ATCC Deposit
Before the U.S. filing date of the present application, a sample of the microorganism (Merck Culture Collection MA 7065) was deposited at the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, MD 20852. The culture access designation is . This deposit will be maintained in the ATCC for at least 30 years and will be made available to the public upon the grant of a patent disclosing it. It should be understood that the availability of a deposit does not constitute a license to practice the subject invention in derogation of patent rights granted by government action.
General Characteristics of ATCC
The physical characteristics and taxonomy, including moφhological, cultural, biological and physiological characteristics are briefly described hereinbelow.
On the basis of the taxonomic analysis performed thus far, the culture has been assigned to the order Streptomyces.
The following is a general description of Streptomyces sp. MA7065 (AS2023, CRA-3-4 ATCC ). This culture produces analogs of Compound J, an inhibitor of HIV protease, by biotransformation. Observations of growth, general cultural characteristics and carbon source utilization were made in accordance with the methods of Shirling and Gottleib (Internal. J. System. Bacterial. 16, 313 - 340). Chemical composition of the cells was determined using the methods of Lechevalier and Lechevalier (in Actinomycete Taxonomy, A. Dietz and D. W. Thayer, Ed., Society for Industrial Microbiology, 1980). Whole cell fatty acids were derivatized and analyzed as methyl esters (FAMEs) by gas chromatography by the procedure of Miller and Berger using a MIDI Microbial Identification System (Microbial Identification Systems. Newark, Delaware). Coloration of the culture was determined by comparison with color standards contained in the Inter-Society Color Council -National Bureau
of Standards Centroid Color Charts (US Dept. of Commerce National Bureau of Standards supplement to NBS Circular 553, 1985).
Source - Culture MA7065 was isolated from a soil sample collected in a fire-break beside a fallow field that had undergone controlled burning 48h prior to sampling. The field was located in Santa Rosa Park, Guanacaste PR, Costa Rica.
Chemotaxonomic characteristics - The peptidoglycan of MA7065 contains LL-diaminopimelic acid. Major whole cell fatty acids are listed in Table 1.
TABLE 1
Major Whole Cell Fatty
Acids Found in MA7065
Fatty acid % age
14:0 iso 6.04
15:0 iso 10.56
15:0 anteiso 9.61
15:0 2.23
16:0 iso H 7.77
16:0 iso 28.50
15:0 iso 2 OH 4.81
15:0 anteiso 2 OH 3.55
16:0 3.55
17:0 anteiso C 4.01
17:0 iso 4.09
17:0 anteiso 4.71
16:0 iso 20H 3.31
18: 1 iso H 1.60
General growth characteristics - Good to excellent growth was observed on yeast-extract malt-extract agar, glycerol-asparagine,
inorganic salts-starch agar, Czapek's agar, Sabouraud Maltose agar, oatmeal agar and trypticase soy broth agar. Fair growth was observed on tap water agar. Growth occurred at 27° and 37 °C. See Table 2.
TABLE 2
Cultural Characteristics of Actinomycete sp. MA7065
Medium Amount of Aerial Soluble Substrate growth mycelium pigments mycelium
Yeast Extract Excellent Light gray (264 l.Gy) None Dark yellow Malt Extract Short, loosely coiled brown (75 d spirals on y.Br) pseudoverticils
Glucose Good Light gray (264 l.Gy) None Dark orange Aspargine Short, loosely coiled yellow (72d. spirals on OY) pseudoverticils
Inorganic Good Black (267 Black) None Yellowish Salts-Starch Short, loosely coiled white (92 y. spirals on pseudo¬ White) verticils, extensive coalescence
Oatmeal Excellent Light gray (264 l.Gy) None Grayish yellow Short, loosely coiled (90 gy.Y) spirals on pseudoverticils
Czapek Good White (263 White) None Grayish yellow Flexous filaments, (90 gy.Y) few spirals
Tap Water Fair Light gray (264 l.Gy) None Colorless Short, loosely coiled spirals on pseudoverticils. highly fragmented Peptone Iron H2S negative, Melanin neεative
Colony morphology - (On yeast-malt agar at 2 Id) Substrate mycelium is a dark yellow brown. Aerial spore mass is abundant, cottony and yellowish gray in color. Colonies are opaque, raised, with an entire edge and matte surface. The colonies are rubbery in texture.
Micromorphology - Aerial mycelia (0.57 μm) arise from substrate mycelia in a verticilate fashion. In mature cultures (7 - 28d p.i.) the aerial mycelium terminates in chains of spores that occur as short, loosely coiled spirals. Sporulation occurs on yeast extract malt extract agar, inorganic salts-starch agar, oatmeal, glycerol asparagine agar, Czapek's agar and tap-water agar. The aerial spore mass coalesces on inorganic salts-starch agar.
Miscellaneous physiological reactions - Culture does not produce H2S in peptone-iron agar. Melanoid pigments were not formed in either peptone-iron agar or tryptone-yeast extract broth. Starch was weakly hydrolyzed. Carbon source utilization pattern is as follows: good utilization of D-arabinose, L-arabinose, D-fructose, α-D-glucose, inositol, -D-lactose, β-D-lactose, D-maltose, D-mannitol, D-mannose, L-rhamnose, and sucrose; moderate utilization of D-raffinose and D-xylose. See Table 3.
TABLE 3
Carbon Source Utilization Pattern of Strains MA7065
Carbon source Growth
D-arabinose 2
L-arabinose 2
D-fructose 3 inositol 3 α-D-lactose 3 β-D-lactose 3
D-maltose 3
D-mannitol 3
D-mannose 3
D-raffinose 3
L-rhamnose 2 sucrose 3
D-xylose 2 α-D-glucose (control) 3
3=good utilization, 2= moderate utilization, l=poor uti ization,
0=no utilization
Diagnosis - Cell wall analysis reveals that MA7065 has a type I cejl wall. Moφhological studies reveal that the culture produces short chains of spores on spiral sporophores, arranged in pseudoverticils which arise from the aerial mycelium. These are characteristics that are typical for some strains of Streptomyces spp. A comparison of the phenotypic data for MA7065 with that of the validly published species of Streptomyces in the taxonomic literature shows that this strain bears some resemblance to Streptomyces albo riseolus, Stmy. lydicus, Stmy. parvulus and Stmy. rochcii. Of these species, only Stmy. lydicus has been reported to exhibit coalescence of the aerial spore mass. However, the sporophores of Stmy. lydicus are not arranged in pseudoverticles.
Comparison of the fatty acid profile of MA7065 against the MIDI actinomycete library (Version 3.7) showed a distant match to Stmy. lydicus.
A cluster analysis was done by furthest neighbor analysis using Euclidean distance as the metric. The results of this analysis showed MA7065 to be more similar to Stmy. lydicus than the other reference strains. These findings are consistent with moφhological and physiological data. Based upon these findings, MA7065 is a novel strain of Stmy. lydicus. The preferred sources of nitrogen are yeast extract, meat extract, peptone, gluten meal, cottonseed meal, soybean meal and other vegetable meals (partially or totally defatted), casein hydrolysates, soybean hydrolysates, and yeast hydrolysates, co steep liquor, dried yeast, wheat germ, feather meal, peanut powder, distiller's solubles, etc., as well as inorganic and organic nitrogen compounds such as ammonium salts (e.g., ammonium nitrate, ammonium sulfate, ammonium phosphate, etc.), urea, amino acids, and the like.
The carbon and nitrogen sources, though advantageously employed in combination, need not be used in their pure form, because less pure materials which contain traces of growth factors and considerable quantities of mineral nutrients, are also suitable for use. When desired, there may be added to the medium mineral salts such as sodium or calcium carbonate, sodium or potassium phosphate, sodium or potassium chloride, sodium or potassium iodide, magnesium salts, copper salts, cobalt salts, and the like. If necessary, especially when the culture medium foams seriously, a defoaming agent, such as liquid paraffin, fatty oil, plant oil, mineral oil or silicone may be added. The compounds of this invention can also be obtained by synthetic organic procedures by a skilled artisan.
As to the conditions for the production of MA7065 in massive amounts, submerged aerobic cultural conditions are preferred. For the production in small amounts, a shaking or
surface culture in a flask or bottle is employed. Furthermore, when the growth is carried out in large tanks, it is preferable to use the vegetative forms of the organism for inoculation in the production tanks in order to avoid growth lag in the process of production. Accordingly, it is desirable first to produce a vegetative inoculum of the organism by inoculating a relatively small quantity of culture medium with spores or mycelia of the organism produced in a "slant" and culturing said inoculated medium, also called the "seed medium", and then to transfer the cultured vegetative inoculum aseptically to large tanks. The fermentation medium, in which the inoculum is produced, is generally autoclaved to sterilize the medium prior to inoculation.
Agitation and aeration of the culture mixture may be accomplished in a variety of ways. Agitation may be provided by a propeller or similar mechanical agitation equipment, by revolving or shaking the fermentor, by various pumping equipment or by the passage of sterile air through the medium. Aeration may be effected by passing sterile air through the fermentation mixture.
The fermentation is usually conducted at a temperature between about 20°C and 40°C, preferably 25-35°C, for a period of about 10 hours to 64 hours, which may be varied according to fermentation conditions and scales. Preferably, the production cultures are incubated for about 48 hours at 28°C on a rotary shaker operating at 220 φm, wherein the pH of the fermentation medium is maintained at 4.85 to harvest.
Preferred culturing/production media for carrying out the fermentation include the following media:
Seed medium (KE medium) consisted of: 0.1 % dextrose; 1 % dextrin; 0.3% beef extract; 0.5% ardamine pH; 0.5% NZ amine type E; 0.005% MgSθ4-7H2θ, and 0.037% K2HPO4 with pH adjusted to 7.1 with 0.05% CaC03. Biotransformation medium (soy-glucose) contained: 2% glucose; 0.5% soya meal; 0.5% yeast extract; 0.5% NaCl; 0.98% MES with pH adjusted to 7.0.
The products can be recovered from the culture medium by conventional means which are commonly used for the recovery of other known substances. The substances produced are obtained by filtering or centrifuging the cultured broth, by a conventional method such as concentration under reduced pressure, lyophilization, extraction with a conventional solvent, such as methylene chloride or methanol and the like, pH adjustment, treatment with a conventional resin (e.g., anion or cation exchange resin, non-ionic adsoφtion resin, etc.), treatment with a conventional adsorbent (e.g., activated charcoal, silicic acid, silica gel, cellulose, alumina, etc.), crystal¬ lization, recrystallization, and the like.
The compounds of this invention are useful in the preparation and execution of screening assays for antiviral compounds. For example, the compounds of this invention are useful for isolating enzyme mutants, which are excellent screening tools for more powerful antiviral compounds. Furthermore, the compounds of this invention are useful in establishing or determining the binding site of other antivirals to HIV protease, e.g., by competitive inhibition. Thus the compounds of this invention are commercial products to be sold for these puφoses. The compounds of the present invention are useful in the inhibition of HIV protease, the prevention or treatment of infection by the human immunodeficiency virus (HIV) and the treatment of consequent pathological conditions such as AIDS. Treating AIDS or preventing or treating infection by HIV is defined as including, but not limited to, treating a wide range of states of HIV infection: AIDS, ARC (AIDS related complex), both symptomatic and asymptomatic, and actual or potential exposure to HIV. For example, the compounds of this invention are useful in treating infection by HIV after suspected past exposure to HIV by, e.g., blood transfusion, organ transplant, exchange of body fluids, bites, accidental needle stick, or exposure to patient blood during surgery.
For these puφoses, the compounds of the present invention may be administered orally, parenterally (including subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion
techniques), by inhalation spray, or rectally, in dosage unit formulations containing conventional non-toxic pharmaceutically-acceptable carriers, adjuvants and vehicles.
Thus, in accordance with the present invention there is further provided a method of treating and a pharmaceutical composition for treating HIV infection and AIDS. The treatment involves administering to a patient in need of such treatment a pharmaceutical composition comprising a pharmaceutical carrier and a therapeutical ly effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof.
These pharmaceutical compositions may be in the form of orally-administrable suspensions or tablets; nasal sprays; sterile injectable preparations, for example, as sterile injectable aqueous or oleagenous suspensions or suppositories. When administered orally as a suspension, these compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may contain microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweetners/flavoring agents known in the art. As immediate release tablets, these compositions may contain microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants known in the art. When administered by nasal aerosol or inhalation, these compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absoφtion promoters to enhance bioavailability, fluorocarbons. and/or other solubilizing or dispersing agents known in the art.
The injectable solutions or suspensions may be formulated according to known art, using suitable non-toxic, parenterally- acceptable diluents or solvents, such as mannitol, 1 ,3-butanediol. water. Ringer's solution or isotonic sodium chloride solution, or suitable
dispersing or wetting and suspending agents, such as sterile, bland, fixed oils, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
When rectally administered in the form of suppositories, these compositions may be prepared by mixing the drug with a suitable non- irritating excipient, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures, but liquidify and/or dissolve in the rectal cavity to release the drug.
Dosage levels of the order of 0.02 to 5.0 or 10.0 grams- per-day are useful in the treatment or prevention of the above-indicated conditions, with oral doses two-to-five times higher. For example, infection by HIV is effectively treated by the administration of from 1.0 to 50 milligrams of the compound per kilogram of body weight from one to four times per day. In one preferred regimen, dosages of 100- 400 mg every six hours are administered orally to each patient. It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.
The present invention is also directed to combinations of the HIV protease inhibitory compounds with one or more agents useful in the treatment of AIDS. For example, the compounds of this invention may be effectively administered, whether at periods of pre- exposure and/or post-exposure, in combination with effective amounts of the AIDS antivirals, immunomodulators, anti-infectives, or vaccines known to those of ordinary skill in the art.
TABLE C
ANTIVIRALS
Drug Name Manufacturer Indication
AL-721 Ethigen ARC, PGL
(Los Angeles, CA) HIV positive, AIDS
Recombinant Human Triton Biosciences AIDS, Kaposi's lnterferon Beta (Almeda, CA) sarcoma, ARC
Acemannan Carrington Labs ARC (Irving, TX) (See also immunomodulators)
Cytovene Syntex sight threatening CMV
Ganciclovir (Palo Alto, CA) peripheral CMV retinitis
d4T Bristol-Myers AIDS, ARC
Didehydrodeoxy- (New York, NY) thymidine
ddl Bristol-Myers AIDS, ARC Dideoxyinosine (New York, NY)
EL10 Elan Coφ, PLC HIV infection (Gainesville, GA) (See also immunomodulators)
Drug Name Manufacturer Indication
Trisodium Astra Pharm. CMV retinitis, HIV Phosphonoformate Products, Inc infection, other CMV
(Westborough, MA) infections
Dideoxycytidine; Hoffman-La Roche AIDS, ARC ddC (Nutley, NJ)
Novapren Novaferon Labs, Inc. HIV inhibitor (Akron, OH) Diapren, Inc. (Roseville, MN, marketer)
Peptide T Peninsula Labs AIDS
Octapeptide (Belmont, CA)
Sequence
Zidovudine; AZT Burroughs Wellcome AIDS, adv, ARC AIDS, adv, ARC (Rsch. Triangle Park, pediatric AIDS, NC) Kaposi's sarcoma, asymptomatic HIV infection, less severe HIV disease, neurological involvement, in combination with other therapies.
Ansamycin LM 427 Adria Laboratories ARC (Dublin, OH) Erbamont (Stamford, CT)
Drug Name Manufacturer Indication
Dextran Sulfate Ueno Fine Chem. AIDS, ARC, HIV Ind. Ltd. positive asymptomatic (Osaka, Japan)
Virazole Viratek/ICN asymptomatic HIV Ribavirin (Costa Mesa, CA) positive, LAS, ARC
Alpha Interferon Burroughs Wellcome Kaposi's sarcoma, (Rsch. Triangle HIV in combination
Park, NC) w/Retrovir
Acyclovir Burroughs Wellcome AIDS, ARC, asymptomatic HIV positive, in combination with AZT.
Antibody which Advanced Biotherapy AIDS, ARC neutralizes pH Concepts labile alpha aberrant (Rockville, MD) Interferon in an immuno-adsoφtion column
B Merck AIDS, ARC, (Rahway, NJ) asymptomatic HIV positive, also in combination with AZT.
Drue Name Manufacturer Indication
C Merck AIDS, ARC,
(Rahway, NJ) asymptomatic HIV positive, also in combination with AZT.
Nevirapine Boehringer AIDS, ARC,
Ingelheim asymptomatic HIV positive, also in combination with AZT.
IMMUNO-MODULATORS
Drug Name Manufacturer Indication
AS-101 Wyeth-Ayerst Labs. AIDS (Philadelphia, PA)
Bropirimine Upjohn advanced AIDS (Kalamazoo, MI)
Acemannan Carrington Labs, Inc. AIDS, ARC (See also (Irving, TX) anti-virals)
CL246,738 American Cyanamid AIDS, Kaposi's (Pearl River, NY) sarcoma Lederle Labs (Wayne, NJ)
EL10 Elan Coφ, PLC HIV infection (Gainesville, GA) (See also anti¬ virals)
Gamma Interferon Genentech ARC, in combination
(S. San Francisco, w/TNF (tumor
CA) necrosis factor)
Drug Name Manufacturer Indication
Granulocyte Genetics Institute AIDS
Macrophage Colony (Cambridge, MA)
Stimulating Sandoz
Factor (East Hanover, NJ)
Granulocyte Hoeschst-Roussel AIDS
Macrophage Colony (Somerville, NJ)
Stimulating Immunex
Factor (Seattle, WA)
Granulocyte Schering-Plough AIDS
Macrophage Colony (Madison, NJ)
Stimulating Factor AIDS, in combination w/AZT
HIV Core Particle Rorer seropositive HIV
Immunostimulant (Ft. Washington, PA)
IL-2 Cetus AIDS, in combination
Interleukin-2 (Emeryville, CA) w/AZT
IL-2 Hoffman-La Roche AIDS, ARC, HIV, in
Interleukin-2 (Nutley, NJ) combination w/AZT Immunex
Immune Globulin Cutter Biological pediatric AIDS, in
Intravenous (Berkeley, CA) combination w/AZT
(human)
Drug Name Manufacturer Indication
IMREG-1 Imreg AIDS, Kaposi's
(New Orleans, LA) sarcoma, ARC, PGL
IMREG-2 Imreg AIDS, Kaposi's
(New Orleans, LA) sarcoma, ARC, PGL
Imuthiol Diethyl Merieux Institute AIDS, ARC Dithio Carbamate (Miami, FL)
Alpha-2 Schering Plough Kaposi's sarcoma Interferon (Madison, NJ) w/AZT: AIDS
Methionine- TNI Pharmaceutical AIDS, ARC Enkephalin (Chicago, IL)
MTP-PE Ciba-Geigy Coφ. Kaposi's sarcoma
Muramyl- (Summit, NJ)
Tripeptide
Granulocyte Amgen AIDS, in combination Colony Stimulating (Thousand Oaks, CA) w/AZT Factor
rCD4 Genentech AIDS, ARC
Recombinant (S. San Francisco, Soluble Human CD4 CA)
rCD4-IgG AIDS, ARC hybrids
Drue Name Manufacturer Indication
Recombinant Biogen AIDS, ARC
Soluble Human CD4 (Cambridge, MA)
Interferon Hoffman-La Roche Kaposi's sarcoma
Alfa 2a (Nutley, NJ) - AIDS, ARC, in combination w/AZT
SK&F106528 Smith, Kline & HIV infection
Soluble T4 French Laboratories (Philadelphia, PA)
Thymopentin Immunobiology HIV infection Research Institute (Annandale, NJ)
Tumor Necrosis Genentech ARC, in combination
Factor; TNF (S. San Francisco, w/gamma Interferon CA)
ANTI-INFECTIVES
Drue Name Manufacturer Indication
Clindamycin with Upjohn PCP
Primaquine (Kalamazoo, MI)
Fluconazole Pfizer cryptococcal
(New York, NY) meningitis, candidiasis
96/12492 PC17US95/13628
23
Drug Name Manufacturer Indication
Pastille Squibb Coφ. prevention of
Ny statin Pastille (Princeton, NJ) oral candidiasis
Ornidyl Merrell Dow PCP Eflornithine (Cincinnati, OH)
Pentamidine LyphoMed PCP treatment
Isethionate (IM & IV) (Rosemont, IL)
Trimethoprim antibacterial
Trimethoprim/sulfa antibacterial
Piritrexim Burroughs Wellcome PCP treatment (Rsch. Triangle Park, NC)
Pentamidine Fisons Coφoration PCP prophylaxis isethionate for (Bedford, MA) inhalation
Spiramycin Rhone-Poulenc cryptosporidial Pharmaceuticals diarrhea (Princeton, NJ)
Intraconazole- Janssen Pharm. histoplasmosis; R5121 1 (Piscataway, NJ) cryptococcal meningitis
Trimetrexate Warner-Lambert PCP
OTHER
Dru Name Manufacturer Indication
Recombinant Human Ortho Pharm. Coφ. severe anemia Erythropoietin (Raritan, NJ) assoc. with AZT therapy
Megestrol Acetate Bristol-Myers treatment of (New York, NY) anorexia assoc. w/AIDS
Total Enteral Norwich Eaton diarrhea and Nutrition Pharmaceuticals malabsoφtion
(Norwich, NY) related to AIDS
It will be understood that the scope of combinations of the compounds of this invention with AIDS antivirals, immunomodulators, anti-infectives or vaccines is not limited to the list in the above Table, but includes in principle any combination with any pharmaceutical composition useful for the treatment of AIDS.
Certain compounds of Table C are the following: Compound B is 6-chloro-4-(S)-cyclopropyl-3,4-dihydro-4-((2- pyridyl)ethynyl)quinazolin-2( 1 H)-one;
Compound C is(-) 6-chloro-4(S)-trifluoromethyl- l ,2-dihydro-4(H)-3, l - benzoxazin-2-one; nevirapine is 1 1 -cyclopropy 1-5, 1 1 -dihydro-4-methy 1- 6 /-dipyrido[3,2- ?:2',3'-<?][ l ,4]diazepin-6-one. Compounds B and C are synthesized by the methods of EP 0,569,083, herein incoφorated by reference for this puφose. Nevirapine is synthesized by Klunder, J. M. et ai, J. Med. Chem. 35, 1887 ( 1992); Hargrave, K. D. et al., J. Med Chem. 34, 2231 ( 1991); Cohen, K. A. et al. '. Biol. Chem. 266, 14670 ( 1991 ), all three references herein incoφorated by reference. Preferred combinations are simultaneous or alternating treatments of an inhibitor of HIV protease and a non-nucleoside
inhibitor of HIV reverse transcriptase. An optional third component in the combination is a nucleoside inhibitor of HIV reverse transcriptase, such as AZT, ddC or ddl. A preferred inhibitor of HIV protease is Compound A. Preferred non-nucleoside inhibitors of HIV reverse transcriptase include Compound B, Compound C or nevirapine. These combinations may have synergistic effects on limiting the spread of HIV. Preferred combinations include the following ( 1 ) Compound A, with a preferred non-nucleoside inhibitor of HIV reverse transcriptase, and, optionally, AZT or ddl or ddC; (2) Compound A, and any of AZT or ddl or ddC.
Assay for Inhibition of Microbial Expressed HIV Protease
Inhibition studies of the reaction of the protease expressed in Eschericia coli with a peptide substrate [Val-Ser-Gln-Asn- (betanapthyl)Ala-Pro-Ile-Val, 0.5 mg/mL at the time the reaction is initiated] were in 50 mM Na acetate, pH 5.5, at 30°C for 1 hour. Various concentrations of inhibitor in 1.0 μl DMSO were added to 25 μl of the peptide solution in water. The reaction is initiated by the addition of 15 μl of 0.33 nM protease (0.1 1 ng) in a solution of 0.133 M Na acetate pH 5.5 and 0.1 % bovine serum albumin. The reaction was quenched with 160 μl of 5% phosphoric acid. Products of the reaction were separated by HPLC (VYDAC wide pore 5 cm C- 18 reverse phase, acetonitrile gradient, 0.1 % phosphoric acid). The extent of inhibition of the reaction was determined as IC50 from the peak heights of the products. HPLC of the products, independently synthesized, proved quantitation standards and confirmation of the product composition.
CELL SPREAD ASSAY
Inhibition of the spread of HIV in cell culture was measured according to Nunberg, J. H. et al., J. Virol. 65, 4887 (1991 ). In this assay, MT-4 T-lymphoid cells were infected with HIV- 1 (wild- type, unless otherwise indicated) by using a predetermined inoculum, and cultures were incubated for 24 h. At this time, <1 % of the cells
were positive by indirect immunofluorescence. Cells were then extensively washed and distributed into 96-well culture dishes. Serial twofold dilutions of inhibitor were added to the wells, and cultures were continued for 3 additional days. At 4 days postinfection, 100% of the cells in control cultures were infected. HIV-1 p24 accumulation was directly correlated with virus spread. The cell culture inhibitory concentration was defined as the inhibitor concentration in nanomoles/liter which reduced the spread of infection by at least 95%, or CIC95-
INHIBITION OF VIRUS SPREAD
A. Preparation of HIV-infected MT-4 cell Suspension. MT cells were infected at Day 0 at a concentration of 250,000 per ml with a 1 : 1000 dilution of HIV-1 strain Illb stock (final 125 pg p24/ml; sufficient to yield <1 % infected cells on day 1 and 25- 100% on day 4). Cells were infected and grown in the following medium: RPMI 1640 (Whittaker BioProducts), 10% inactivated fetal bovine serum, 4 mM glutamine (Gibco Labs) and 1 : 100 Penicillin- Streptomycin (Gibco Labs).
The mixture was incubated overnight at 37°C in 5% C02 atmosphere.
B. Treatment with Inhibitors A matrix of nanomolar range concentrations of the pairwise combinations is prepared. At Day 1 , aliquots of 125 μl of inhibitors are added to equal volumes of HIV-infected MT-4 cells (50,000 per well) in a 96-well microtiter cell culture plate. Incubation is continued for 3 days at 37°C in 5% CO2 atmosphere.
C. Measurement of Virus Spread
Using a multichannel pipettor, the settled cells are resuspended and 125 μl harvested into a separate microtiter plate. The supernatant is assayed for HIV p24 antigen.
The concentration of HIV p24 antigen is measured by an enzyme immunoassay, described as follows. Aliquots of p24 antigen to be measured are added to microwells coated with a monoclonal antibody specific for HIV core antigen. The microwells are washed at this point, and at other appropriate steps that follow. Biotinylated HIV-specific antibody is then added, followed by conjugated streptavidin- horseradish peroxidase. A color reaction occurs from the added hydrogen peroxide and tetramethylbenzidine substrate. Color intensity is proportional to the concentration of HIV p24 antigen.
Calculation of Degree of Synergy or Enhanced Inhibition
When there is synergy pairwise combinations of inhibitors are found to exhibit markedly enhanced inhibition of virus spread, in comparison to each inhibitor alone, or in comparison to merely additive inhibition of each inhibitor.
The data is processed as follows: fractional inhibitory concentration ratios (FIC) are calculated according to Elion, et ai, J. Biol. Chem., 208, All ( 1954). The minimum sum of FICS, which is the maximum synergy, is determined for various pairwise combinations. The smaller the number, the greater the synergy.
EXAMPLE 1
A. Culture Preparation Culture MA7065 was grown in seed and biotransformation media, respectively. Seed medium (KE medium) consisted of: 0.1 % dextrose; 1 % dextrin; 0.3% beef extract; 0.5% ardamine pH; 0.5% NZ amine type E; 0.005% MgSθ4«7H2θ, and 0.037% K2HPO4 with pH adjusted to 7.1 with 0.05% CaC03. Biotransformation medium (soy- glucose) contained: 2% glucose; 0.5% soya meal; 0.5% yeast extract; 0.5% NaCl: 0.98% MES with pH adjusted to 7.0.
B. Biotransformation Screening
MA7065 was grown in KE seed medium. After overnight incubation at 27°C with gyratory shake (220 φm) two milliliters of each culture was transferred into 250 ml baffled flasks containing 50 ml of soy-glucose bioconversion medium. At zero time, 5 mg of
Compound J, dissolved in 0.5 ml DMSO, was added to each flask and incubation continued as for seed culture. At various time intervals, a sample of the biotransformation culture was examined by HPLC. At the time of maximal conversion of the substrate, as determined by HPLC, the cultures were harvested and subjected to isolation, purification and characterization.
C. Isolation and Characterization of the Biotransformation Products The content of ten flasks initially containing 25 mg of the
HIV-protease inhibitor, Compound J, were pooled and centrifuged. The supernatant was recovered and applied on the top of an activated column containing 14% octadecyl support. The column was washed with water and then eluted with a gradient of an aqueous methanol from 20 to 80%. Each eluted fraction was examined by HPLC on an analytical column. This column was developed with a gradient solvent system consisting of reservoir A and B. Reservoir A contained 10% ammonium acetate : 0.1 % formic acid and reservoir B contained 67% acetonitrile : 33% methanol : 0.1 % formic acid. The gradient was run from 30 to 85% solvent B in 30 min. Based on the result from the analytical column, fractions containing desired metabolites were eluted with 60 to 80% aqueous methanol from the activated column. This fraction was therefore further purified on a semi-prep. Four resolved fractions from the analytical column was each isolated and after further purification were submitted for NMR, FAB-MS analysis and biological evaluation.
EXAMPLE 2
Four samples isolated from an incubation of the HIV protein inhibitor Compound J with bacterial culture MA7065 were characterized by mass spectral analysis. As shown below, Compounds A, Cl , C2, D and E were characterized. Oxidation of the indanyl, phenyl, and pyridine rings was observed.
Mass spectra and daughter ion spectra were obtained by LC/MS/MS on a mass spectrometer using the ionspray interface. Samples were analyzed by direct injection in a mobile phase that consisted of 50% CH3CN/50% 10 mM NH4θAc/0.1 % TFA. Positive ion detection was used.
Compound J
The mass spectrum of J gave an (M+H)+ = 614, which indicated a molecular weight of 613 Da. Four key fragment ions in the daughter ion spectrum of J at m/z 513, 465, 421 , and 338, made it possible to determine the general site of metabolism for these samples. The following table summarizes the results of the analysis of these spectra and includes samples of MA7065 biotransformation products (68051 -A, 68051 -9C, 68051 -12 Fl and 68051 -12 F3) as well as products from other microorganisms.
TABLE
Sample Compound Mol. Weight Addition of: Site of Addition
68051 -5 X 1 645 two hydroxyls phenyl, indanyl
68051 -5 X2 629 hydroxyl indanyl
68051 -5 X3 627 ketone indanyl
68051 -9 A* (E) 629 oxygen pyridine
+ 629 hydroxyl indanyl
68051 -9 B 629 hydroxyl indanyl
68051 -9 C 629 hydroxyl indanyl
68051 -12 Fl (Cl & C2) 629 hydroxyl indane
68051 - 12 F2 (D) 629 hydroxyl phenyl
68051 - 12 F3 (E) 629 oxygen pyridine A hydroxyl indanyl
* Sample was determined to be a mixture of two oxygenated compounds
The structures of these compounds were conformed by NMR spectroscopic analysis.
EXAMPLE 3
HIV Protease Inhibitory Activity of Compound J Bioconversion
Products
Seven Compound J bioconversion products were assayed for in vitro HIV protease inhibitory by the assay for inhibition of microbial expressed HIV Protease, protocol given above. Four of the bioconversion products were isolated from MA7065 incubations, Compounds A, Cl , C2. D and E. The IC50 of the parent Compound J
was divided by the IC50 of each test compound and multiplied by 100 in order to calculate the percent potency of each compound relative to J.
In some cases, the dilution of the test compound was based on nominal weight. In other cases, especially when the weight was less than 250 μg, the concentration was checked by HPLC using J as standard.
% Potency Relative to Compound J
Based On Compound Wt. Ree d Nominal Wt. Based on HPLC
A 750 μg 27% -—a
(2,3-Trans-OH)
B 240 μg -—a 1 15%
(2,3-Cis-OH)
C 50 μg 8.6% 86%
(5- or 6-OH-Indane)
D 50 μg 3.1 % 31 %
(p-OH-Phenyl)
E 250 μg 34% —-a
(N-Oxide)
F 1000 μg 16% -—a
(3-Ketone)
aNot calculated
EXAMPLE 4
Preparation of Amide 1
A solution of (-)-cis- l -aminoindan-2-ol (884 g, 5.93 mol) in 17.8 L of dry THF (KF = 55 mg/mL) (KF stands for Karl Fisher titration for water) and triethylamine (868 mL, 6.22 mol) in a 50 L round bottom flask equipped with a thermocouple probe, mechanical stirrer, and a nitrogen inlet adapter and bubbler, was cooled to 15°C. Then. 3-phenylpropionyl chloride ( 1000 g, 5.93 mol) was added over 75 minutes, while the internal temperature was kept between 14-24°C with an ice-water cooling batch. After addition, the mixture was aged at 18 to 20°C for 30 minutes and checked by HPLC analysis for the disappearance of (-)-cis- l -aminoindan-2-ol.
Progress of the reaction is monitored by high performance liquid chromatography (HPLC) analysis: 25 cm Dupont C8-RX column, 60:40 acetonitrile/10 mM (KH2PO4/K2HPO4), 1.0 mL/min, injection volume = 20 mL, detection = 200 nm, sample preparation = 500 X dilution. Approximate retention times:
retention time (min) identity 6.3 cis-aminoindanol
The reaction was treated with pyridinium -toluene- sulfonate (241 g, 0.96 mol, 0.16 equiv.) and stirred for 10 minutes (the pH of the mixture after diluting 1 mL sample with an equal volume of water is between 4.3-4.6). Then, 2-methoxypropene ( 1.27 L, 13.24 mol, 2.2 equiv.) was added and reaction was heated to 38-40°C for 2 h.
The reaction mixture was cooled to 20°C and partitioned with ethyl acetate ( 12 L) and 5% aqueous NaHCθ3 (10 L). The mixture was agitated and the layers were separated. The ethyl acetate extract was washed with 5% aqueous NaHC03 (10 L) and water (4 L). The ethyl acetate extract was dried by atmospheric distillation and solvent switched to cyclohexane (total volume of ~30L). At the end of the distillation and concentration (20 volume % of ethyl acetate extraction volume), the hot cyclohexane solution was allowed to slowly cool to 25°C to crystallize the product. The resulting slurry was further cooled to 10°C and aged for 1 h. The product was isolated by filtration and the wet cake was washed with cold ( 10°C) cyclohexane (2 X 800 mL). The washed cake was dried under vacuum (26" of Hg) at 40°C to afford 1.65 kg of acetonide 1 (86.4%, 98 area% by HPLC), lH NMR (300.13 MHz, CDC13, major rotamer) δ 7.36-7.14 (m, 9 H), 5.03 (d, J=4.4, 1 H), 4.66 (m, 1 H) 3.15 (m, 2 H), 3.06 (br s, 2 H), 2.97 (m, 2 H), 1.62 (s, 3 H), 1.37 (s, 3 H); 13c NMR (75.5 MHz, CDCI3. major rotamer) δc 168.8, 140.9, 140.8, 140.6, 128.6, 128.5, 128.4, 127.1 , 126.3, 125.8, 124.1, 96.5, 78.6, 65.9, 38.4, 36.2, 31.9, 26.5, 24.1. Anal. Calcd for C21 H23N02: C, 78.47; H. 7.21 ; N, 4.36. Found: C, 78.65; H, 7.24; N, 4.40.
EXAMPLE 5
Preparation of Epoxide 3
A solution of acetonide 1 ( 1000 g, 3.1 1 mol) and 2(S)- glycidyl tosylate 2 (853 g, 3.74 mol, 1.2 equiv.) in 15.6 L of THF (KF = 22 mg/mL) in a 50 L 4-neck round bottom flask, equipped with a thermocouple, mechanical stirrer, addition funnel and nitrogen inlet adapter was degassed 3 times via vacuum-nitrogen purge and cooled to -56°C. Then, lithium hexamethyldisilazide (LiN[(CH3)3Si]2)(2.6 L, 1.38 M, 1.15 equiv.) was added over 2 h, while keeping the internal temperature between -50 to -45 °C. The reaction mixture was stirred at -45 to -40°C for 1 h and then allowed to warm to -25°C over 1 h. The mixture is stirred between -25 to -22°C for 4 h (or until the starting acetonide is 3.0 area %).
Progress of the reaction is monitored by HPLC analysis: 25 cm X 4.6 nm Zorbax Silica column, 20% ethyl acetate in hexane, 2.0 mL/min, injection volume = 20 mL, detection = 254 nm, sample preparation = 100 X dilution. Approximate retention times:
retention time (min). identity
5.5 amide 1
6.5 glycidyl tosylate 2
13.5 epoxide 3
The reaction mixture was quenched with DI water (6.7 L) at -15°C and partitioned with ethyl acetate ( 10 L). The mixture was agitated and the layers were separated. The ethyl acetate extract was washed with a mixture of 1 % aqueous NaHCθ3 (5 L) and saturated NaCl (0.5 L). The ethyl acetate extract (28.3 L) was concentrated by vacuum distillation (28" of Hg) and additional ethyl acetate was added to complete the solvent switch to ethyl acetate (final volume = 1 1.7 L). The ethyl acetate concentrate was further solvent switched to MeOH to crystallize the product and concentrated to a final volume of 3.2 L. The residual ethyl acetate solvent was removed by charging 10 L of methanol and collecting 10 L of distillate. The resulting slurry was stirred at 22°C for 1 h, then cooled to 5°C and aged for 0.5 h. The product was isolated by filtration and the wet cake was washed with cold
methanol (2 X 250 mL). The washed cake was dried under vacuum (26" of Hg) at 25°C to afford 727 g of epoxide 3 (61.2%, 98.7 area % of the major epoxide by HPLC): 13c NMR (75.5 MHz, CDC13) δ
171.1 , 140.6, 140.5, 139.6, 129.6, 128.8, 128.2, 127.2, 126.8, 125.6, 124.1 , 96.8, 79.2, 65.8, 50.0, 48.0, 44.8, 39.2, 37.4, 36.2, 26.6, 24.1.
EXAMPLE 6
Preparation of penultimate 6
A slurry of the 2(S)-t-butylcarboxamide-4-/V-Boc- piperazine 4 ( 1950 g, 6.83 mol, >99.5% ee) (ee = enantiomeric excess) and the epoxide 3 (2456 g, 97.5:2.5 mixture of ASIR epoxides, 6.51 mol) in isopropanol (2-propanol, 18.6 L) in a 72 L round bottom flask with four inlets, equipped with a mechanical stirrer, reflux condenser, steam bath, Teflon coated thermocouple and nitrogen inlet, was heated to reflux (internal temperature was 84-85°C). After 40 min, a homogeneous solution was obtained. The mixture was heated at reflux for 28 h.
The internal temperature during reflux was 84-85°C. Progress of the reaction was monitored by HPLC analysis: 25 cm Dupont C8-RX column, 60:40 acetonitrile/10 mM (KH2PO4/K2HPO4),
1.0 mL/min, detection = 220 nm, sample preparation = 2 μL, reaction mixture diluted to 1 mL in acetonitrile. Approximate retention times:
retention time (min) identity
4.8 piperazine 4
8.9 epoxide 3
15.2 coupled product 5
After 28 h, the remaining epoxide 3 and coupled product 5 (by HPLC analysis) were 1.5 area % and 91 -93 area %, respectively. The mixture was cooled to 0 to 5°C and 20.9 L of 6 N HC1 was added while keeping the temperature below 15°C. After the addition was
complete, the mixture was warmed to 22°C. Evolution of gas is noted at this point (isobutylene). The mixture was aged at 20 to 22°C for 6 h. Progress of the reaction was monitored by HPLC analysis: same conditions as above. Approximate retention times:
retention time (min) identity
7.0 cis-aminoindanol
1 1.9 penultimate 6
15.1 coupled product 5
The mixture was cooled to 0°C and 7.5 L of 50% NaOH was slowly added to adjust the pH of the mixture to pH=l 1.6, while keeping the temperature less than 25°C during the addition. The mixture was partitioned with ethyl acetate (40 L) and water (3 L). The mixture was agitated and the layers were separated. The organic phase (60 L) was concentrated under reduced pressure (29" of Hg) and solvent switched to DMF and concentrated to a final volume of 10.5 L (KF = 1.8 mg/mL). The HPLC assay yield of 6 in ethyl acetate was 86.5%. The penultimate compound 6 in DMF was directly used in the next step without further purification. For isolated 6: 13C NMR (75.4 MHz, CDCl3) δ 175.2, 170.5, 140.8, 140.5, 139.9, 129.1 , 128.5, 127.9, 126.8, 126.5, 125.2, 124.2, 73.0, 66.0, 64.8, 62.2, 57.5, 49.5, 47.9, 46.4, 45.3, 39.6, 39.3, 38.2, 28.9. To 10.0 g (0.019 mol) of N-(2(R)-hydroxy-l (S)-indanyl)-
2(R)-phenylmethyl-4(S)-hydroxy)-5-(l(-2(S)-N-(t-butylcarbamoyl)- piperaziny -pentaneamide 6 and 3.45 g (0.021 mol) of 3-picolyl chloride dissolved in 40 mL of DMF was added 5.85 mL (0.042 mol) of triethylamine. After 3 hours an additional 0.313 g of 3-picolyl chloride was added. After an additional 2 hours the reaction was diluted with 400 mL of EtOAc and washed with water (3 x 75 mL), brine (1 x 100 mL), dried over MgSθ4 and concentrated. The residue was triturated with 30 mL of EtOAc and the resulting white precipitate was collected. Further recrystallization from EtOAc provided the product Compound J (m.p. 167.5-168°C).
EXAMPLE 7
Pyrazine-2-tert-butyl carboxamide 9
CONHt-Bu
2-Pyrazinecarboxylic acid (8) 3.35 kg (27 mol)
Oxalyl chloride 3.46 kg (27.2 mol) tert-Butylamine (KF = 460 μg ml) 9.36 L (89 mol)
EtOAc (KF = 56 μg/ml) 27 L
DMF 120 mL
1 -Propanol 30 L
The carboxylic acid 8 was suspended in 27 L of EtOAc and 120 mL of DMF in a 72 L 3-neck flask with mechanical stirring under N2 and the suspension was cooled to 2°C. The oxalyl chloride was added, maintaining the temperature between 5 and 8°C.
The addition was completed in 5 h. During the exothermic addition CO and C02 were evolved. The HC1 that was formed remained largely in solution. A precipitate was present which is probably the HCL salt of the pyrazine acid chloride. Assay of the acid chloride formation was carried out by quenching an anhydrous sample of the reaction with t-butylamine. At completion <0.7% of acid 8 remained.
The assay for completion of the acid chloride formation is important because incomplete reaction leads to formation of a bis-tert- butyl oxamide impurity.
The reaction can be monitored by HPLC: 25 cm Dupont Zorbax RXC8 column with 1 mL/min flow and detection at 250 nm; linear gradient from 98% of 0.1 % aqueous H3PO4 and 2% CH3CN to
50% aqueous H3PO4 and 50% CH3CN at 30 min. Retention times: acid 8 = 10.7 min, amide 9 = 28.1 min.
The reaction mixture was aged at 5°C for 1 h. The resulting slurry was cooled to 0°C and the tert-butylamine was added at such a rate as to keep the internal temperature below 20°C.
The addition required 6 h, as the reaction was very exothermic. A small portion of the generated tert-butylammonium hydrochloride was swept out of the reaction as a fluffy white solid.
The mixture was aged at 18°C for an additional 30 min. The precipitated ammonium salts were removed by filtration. The filter cake was washed with 12 L of EtOAc. The combined organic phases were washed with 6 L of a 3% NaHCθ3 and 2 X 2 L of saturated aq. NaCl. The organic phase was treated with 200 g of Darco G60 carbon and filtered through Solka Flok and the cake was washed with 4 L of EtOAc.
Carbon treatment efficiently removed some puφle color in the product.
The EtOAc solution of 9 was concentrated at 10 mbar to 25% of the original volume. 30 L of 1-propanol were added, and the distillation was continued until a final volume of 20 L was reached.
At this point, the EtOAc was below the limit of detection in the lH NMR (<1 %). The internal temperature in this solvent change was < 30°C. A 1 -propanol/EtO AC solution of 3 was stable to reflux atatmospheric pressure for several days. Evaporation of an aliquot gave a tan solid m.p. 87-88°C. 13c NMR (75 MHz, CDCI3, ppm) 161.8, 146.8, 145.0, 143.8, 142.1 , 51.0, 28.5.
EXAMPLE 8
rac-2-tert-Buty 1-carboxamide-piperazine 10
Materials
Pyrazine-2-tert-butylcarboxamide 9 2.4 kg (13.4 mol) in 1 - Propanol solution 12 L 20% Pd(OH)2/C 16 wt.% water 144 g.
The pyrazine-2-tert-butylcarboxamide 9/1 -propanol solution was placed into the 5 gal autoclave. The catalyst was added and the mixture was hydrogenated at 65°C at 40 psi (3 arm) of H2.
After 24 h the reaction had taken up the theoretical amount of hydrogen and GC indicated <1 % of 9. The mixture was cooled, purged with N2 and the catalyst was removed by filtration through Solka Floe. The catalyst was washed with 2 L of warm 1 -propanol. It was found that the use of warm 1 -propanol during washing of the filter cake improved filtration and lowered the losses of product on the filter cake.
The reaction was monitored by GC: 30 m Megabore column, from 100°C to 160°C at 10°C/min, hold 5 min, then at
10°C/min to 250°C, retention times: 9 = 7.0 min, 10 = 9.4 min. The reaction could also be monitored by TLC with EtOAc/MeOH (50:50) as solvent and Ninhydrin as developing agent.
Evaporation of an aliquot indicated that the yield over amidation and hydrogenation is 88% and that the concentration of 10 is 133g/L.
Evaporation of an aliquot gave 10 as a white solid m.p. 150- 151 °C; 13C NMR (75 MHz, D2θ, ppm) 173.5, 59.8, 52.0. 48.7, 45.0, 44.8, 28.7.
EXAMPLE 9
(S)-2-tert-Butyl-carboxamide-piperazine bis (S)-Camphorsulfonic acid salt (S -11
10 11
Materials rac-2-tert-Butyl-carboxamide-piperazine 10 4.10 kg (22.12 mol) in 1 -Propanol Solution in 25.5 Kg solvent
(S)-(+)-10-Camphorsulfonic acid 10.0 Kg (43.2 mol) 1 -Propanol 12 L
Acetonitrile 39 L
Water 2.4 L
The solution of amine 10 in 1 -propanol was charged to a 100 L flask with an attached batch concentrator. The solution was concentrated at 10 mbar and a temperature < 25°C to a volume of ca 12
L.
At this point the product had precipitated from the solution, but went back into a solution when the mixture was heated to 50°C. Analysis of a homogeneous aliquot indicated that the concentration of 10 was 341 g/L. The concentration was determined by
HPLC: 25 cm Dupont Zorbax RXC8 column with 1.5 mL/min flow and detection at 210 nm, isocratic (98/2) CH3CN/O.I % aqueous H3PO4.
Retention time of 10 : 2.5 min. Acetonitrile (39 L) and water (2.4 L) were added to give a clear, slightly brown solution.
Determination of the water content by KF titration and
CH3CN/I -propanol ratio by lH NMR integration showed that the
CH3CN/l -propanol/H2θ ratio was 26/8/1.6. The concentration in the solution was 72.2 g/ L.
The (S)-lO-camphorsu.fonic acid was charged over 30 min in 4 portions at 20°C. The temperature rose to 40°C after the CSA was added. After a few minutes a thick white precipitate formed. The white slurry was heated to 76°C to dissolve all the solids, the slightly brown solution was then allowed to cool to 21 °C over 8 h.
The product precipitated at 62°C. The product was filtered without aging at 21 °C, and the filter cake was washed with 5 L of the CH3CN / 1 -propanol / H2O 26/8/1.6 solvent mixture. It was dried at 35°C in the vacuum oven with N2 bleed to give 5.6 Kg (39%) of 11 as a white crystalline solid m.p. 288-290°C (with decomp.) lαjD25 = 1 .9° (c = 0.37, H2θ). 13C NMR (75 MHz, D2O, ppm) 222.0, 164.0, 59.3, 54.9, 53.3, 49.0, 48.1 , 43.6, 43.5, 43.1 , 40.6, 40.4, 28.5, 27.2, 25.4, 19.9, 19.8.
The ee of the material was 95% according to the following chiral HPLC assay: an aliquot of 11 (33 mg) was suspended in 4 mL of EtOH and 1 mL of Et3N. Boc2θ ( 1 1 mg) was added and the reaction mixture was allowed to age for 1 h. The solvent was completely removed in vacua, and the residue was dissolved in ca. 1 mL of EtOAc and filtered through a Pasteur pipet with Siθ2, using EtOAc as eluent. The evaporated product fractions were redissolved in hexanes at ca. 1 mg/mL. The enantiomers were separated on a Daicel Chiracell AS column with a hexane/IPA (97:3) solvent system at a flow rate of 1 mL/min and detection at 228 nm. Retention times: S antipode = 7.4 min, R = 9.7 min.
EXAMPLE 10
(S)-2-tert-Butylcarboxamide-4-tert-butoxycarbonyl-piperazine 4 from salt 1 1
CONHt-Bu
11 4
Materials
(S)-2-tert-Butyl-carboxamide-piperazine
Bis (S) - (+) - CSA salt 11, 95% ee 5.54 Kg (8.53 mol)
Di-tert-butyl dicarbonate 1.86 Kg (8.53 mol)
Et3N 5.95L (42.6 mol)
EtOH Punctilious 200 proof 55 L
EtOAc 2 L
To the (S)-CSA salt 11 in a 100 L 3-neck flask with an addition funnel under N2 was added EtOH, followed by triethylamine at 25°C. The solid dissolved readily on the addition of the Et3N. The Boc2θ was dissolved in EtOAc and charged to the addition funnel. The solution of Boc2θ in EtOAc was added at such a rate as to keep the temperature below 25°C. The addition took 3 h. The reaction mixture was aged for 1 h after completion of the addition of the Boc2θ solution. The reaction can be monitored by HPLC: 25 cm Dupont Zorbax RXC8 column with 1 mL/min flow and detection at 228 nm, isocratic (50/50) CH3CN/O.I M KH2PO4 adjusted to pH=6.8 with NaOH. Retention time of 4 = 7.2 min. The chiral assay was carried out using the same system as in the previous step. The reaction could also be monitored by TLC with a 100% EtOAc as the solvent. (Rf=0.7)
The solution was then concentrated to ca. 10 L at an internal temperature of <20°C in a batch-type concentrator under 10 mbar vacuum. The solvent switch was completed by slowly bleeding in
20 L of EtOAc and reconcentrating to ca 10 L. The reaction mixture was washed into an extractor with 60 L of EtOAc. The organic phase was washed with 16 L of 5% aqueous Na2Cθ3 solution, 2 X 10 L Di water and 2 X 6 L of saturated aqueous sodium chloride. The combined aqueous washes were back extracted with 20 L of EtOAc and the organic phase was washed with 2 X 3 L water and 2 X 4 L of saturated aqueous sodium chloride. The combined EtOAc extracts were concentrated under 10 mbar vacuum with an internal temperature of <20°C in a 100 L batch-type concentrator to ca. 8 L. The solvent switch to cyclohexane was achieved by slowly bleeding in ca. 20 L of cyclohexane, and reconcentrating to ca. 8 L. To the slurry was added 5 L of cyclohexane and 280 mL of EtOAc and the mixture was heated to reflux, when everything went into solution. The solution was cooled and seed ( 10 g) was added at 58°C. The slurry was cooled to 22°C in 4 h and the product was isolated by filtration after a 1 h age at 22°C. The filter cake was washed with 1.8 L of cyclohexane and dried' in the vacuum oven at 35°C under N2 bleed to give 1.87 Kg (77%, >99.9 area % by HPLC, R-isomer below level of detection) of 4 as a slightly tan powder. lαlD25 = 22.0° (c = 0.20, MeOH), m.p. 107°C; Be NMR (75 MHz, CDC13, ppm) 170.1 , 154.5, 79.8, 58.7, 50.6, 46.6, 43.6, 43.4, 28.6, 28.3.
While the foregoing specification teaches the principles of the present invention, with examples provided for the puφose of illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adaptations, or modifications, as come within the scope of the following claims and its equivalents.
Claims (11)
1. A method of synthesizing biotransformation products of the Compound J having the structure:
or salt or hydrate thereof, comprising the steps of
(a) providing a culture of MA7065;
(b) incubating said culture with Compound J;
(c) isolating biotransformation products comprising:
or
or salt or hydrate thereof.
2. A purified biotransformation product of the method of Claim 1.
3. The compound, which is
or salt or hydrate thereof.
4. A pharmaceutical composition comprising the compound of Claim 3. and a pharmaceutically acceptable carrier.
5. The pharmaceutical composition of Claim 3, for use in the treatment of and the delaying of the onset of AIDS, in the prevention of infection of HIV, in the treatment of infection of HIV, or in the inhibition of HIV protease.
6. A method of treating and delaying the onset of AIDS, comprising administering to a mammal in need of such treatment an effective amount of a compound of Claim 3.
7. A method of preventing infection by HIV comprising administering to a mammal in need of such treatment an effective amount of a compound of Claim 3.
8. A method of treating infection by HIV, comprising administering to a mammal in need of such treatment an effective amount of a compound of Claim 3.
9. A method of inhibiting HIV protease, comprising administering to a mammal in need of such treatment an effective amount of a compound of Claim 3.
10. A combination of compounds, which is a compound of Claim 3, and any of AZT or ddl or ddC.
1 1. A pure culture of MA7065.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32863494A | 1994-10-25 | 1994-10-25 | |
US328634 | 1994-10-25 | ||
PCT/US1995/013628 WO1996012492A1 (en) | 1994-10-25 | 1995-10-20 | Microbial synthesis of hiv protease inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
AU3966395A true AU3966395A (en) | 1996-05-15 |
AU702122B2 AU702122B2 (en) | 1999-02-11 |
Family
ID=23281761
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU39663/95A Ceased AU702122B2 (en) | 1994-10-25 | 1995-10-20 | Microbial synthesis of HIV protease inhibitors |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0785786A4 (en) |
JP (1) | JPH10507917A (en) |
AU (1) | AU702122B2 (en) |
WO (1) | WO1996012492A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU700744B2 (en) * | 1994-10-25 | 1999-01-14 | Merck & Co., Inc. | Microbial synthesis of HIV protease inhibitors |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5763196A (en) * | 1996-01-26 | 1998-06-09 | Boehringer Mannheim Corporation | Assays using cross-linked polypeptide fragments of β-galactosidase |
US5976857A (en) * | 1996-01-26 | 1999-11-02 | Boehringer Mannheim Corporation | Cross-linked polypeptide fragments of β-galactosidase |
JP2863638B2 (en) * | 1996-01-26 | 1999-03-03 | ベーリンガー マンハイム コーポレイション | Bismaleimide crosslinking agent |
US7569690B2 (en) | 2002-09-05 | 2009-08-04 | Toray Fine Chemicals Co., Ltd. | Process for producing oxycarbonyl-substituted piperazine derivative |
JP2004115510A (en) * | 2002-09-05 | 2004-04-15 | Toray Fine Chemicals Co Ltd | Method for producing piperazine derivative |
CN101497608B (en) * | 2009-03-05 | 2011-11-09 | 中国科学院广州生物医药与健康研究院 | HIV protease inhibitor derivative, preparation thereof and use in antineoplastic medicament preparation |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3160560A (en) * | 1957-08-23 | 1964-12-08 | Upjohn Co | Streptolydigin and production thereof |
JPS5774090A (en) * | 1980-10-27 | 1982-05-10 | Shionogi & Co Ltd | Novel beta-galactosidase inhibitor, gt-2558, its derivative, and production |
CA2081970C (en) * | 1991-11-08 | 1997-07-08 | Joseph P. Vacca | Hiv protease inhibitors useful for the treatment of aids |
CA2110827A1 (en) * | 1992-12-14 | 1994-06-15 | Maki Nishio | Antiviral antibiotic bu-4724v and preparation thereof |
NZ265164A (en) * | 1993-03-31 | 1997-09-22 | Merck & Co Inc | Pharmaceutical composition comprising a pyridinyl-methyl-piperazine derivative and any of azt, ddi or ddc |
US5612217A (en) * | 1994-10-25 | 1997-03-18 | Merck & Co., Inc. | Streptomyces sp. MA 7074 (ATCC 55605) used for microbial synthesis of HIV protease inhibitors |
-
1995
- 1995-10-20 AU AU39663/95A patent/AU702122B2/en not_active Ceased
- 1995-10-20 JP JP8514082A patent/JPH10507917A/en active Pending
- 1995-10-20 WO PCT/US1995/013628 patent/WO1996012492A1/en not_active Application Discontinuation
- 1995-10-20 EP EP95937602A patent/EP0785786A4/en not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU700744B2 (en) * | 1994-10-25 | 1999-01-14 | Merck & Co., Inc. | Microbial synthesis of HIV protease inhibitors |
Also Published As
Publication number | Publication date |
---|---|
AU702122B2 (en) | 1999-02-11 |
EP0785786A4 (en) | 1998-01-28 |
JPH10507917A (en) | 1998-08-04 |
EP0785786A1 (en) | 1997-07-30 |
WO1996012492A1 (en) | 1996-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IE913647A1 (en) | Hydroxylated inhibitors of hiv reverse transcriptase | |
EP0734387B1 (en) | Hiv protease inhibitors | |
EP0696277A1 (en) | Hiv protease inhibitors useful for the treatment of aids | |
KR20050098928A (en) | Substituted heterocycles | |
AU702122B2 (en) | Microbial synthesis of HIV protease inhibitors | |
US6395743B1 (en) | HIV integrase inhibitors | |
US5612217A (en) | Streptomyces sp. MA 7074 (ATCC 55605) used for microbial synthesis of HIV protease inhibitors | |
GB2306476A (en) | Hiv integrase inhibitors | |
US5858737A (en) | Conversion of indene to (1S)-amino-(2R)-indanol free of any stereoisomer, by combination of dioxygenase bioconversion and chemical steps | |
WO1997000966A1 (en) | Conversion of indene to (1s)-amino-(2r)-indanol free of any stereoisomer, by combination of dioxygenase bioconversion and chemical steps | |
KR100453301B1 (en) | 1-Trifluoromethyl-4-Hydroxy-7-Piperidinyl-Aminomethylchroman Derivatives | |
US5605819A (en) | Quantitative conversion of indene to (1S,2R) indene oxide and (1S,2R)-indandiol by combination of haloperoxidase bioconversion and chemical steps | |
CA2203273A1 (en) | Microbial synthesis of hiv protease inhibitors | |
JPH0570448A (en) | Hiv protease inhibitor | |
CA2203272A1 (en) | Microbial synthesis of hiv protease inhibitors | |
GB2327674A (en) | HIV integrase inhibitors | |
US5871981A (en) | Conversion of indene to (1S)-amino-(2R)-indanol free of any steroisomer by combination of fermentation of Rhodococcus sp. ATCC 55805 and chemical steps | |
US6221899B1 (en) | Terpenoid lactone compounds and their production process | |
US6277860B1 (en) | Furopyridine antibacterials | |
EP0933373B1 (en) | Terpenoid lactone compounds and their production process | |
WO1998006865A1 (en) | Conversion of indene to (1s)-amino-(2r)-indanol free of any stereoisomer, by combination of monooxygenase bioconversion and chemical steps | |
EP0432697A2 (en) | BU-4146T antibiotic | |
US5037836A (en) | BU-4146T antibiotic | |
EP0999212A1 (en) | Furopyridine antibacterials |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |